Table 3.
National Potential Savings in State Medicaid Programs from Greater Use of Generic Drugs, Specific Agents, 2000
| Primary Analysis | Best MAC-Price Analysis | ||||
|---|---|---|---|---|---|
| Total Reimbursed | Potential Savings | % Savings | Potential Savings | % Savings | |
| Clozapine | $ 202,761,006 | $ 23,098,582 | 11.4 | $ 67,821,868 | 33.4 |
| Levothyroxine | 68,802,671 | 17,726,624 | 25.8 | 28,157,885 | 40.9 |
| Alprazolam | 35,308,683 | 11,028,311 | 31.2 | 11,628,543 | 32.9 |
| Enalapril | 122,126,165 | 10,530,374 | 8.6 | 31,134,625 | 25.5 |
| Carbamazepine | 84,814,301 | 10,275,413 | 12.1 | 14,077,999 | 16.6 |
| Digoxin | 38,781,930 | 10,075,230 | 26.0 | 17,768,745 | 45.8 |
| Amylase/Lipase/Protease | 37,087,356 | 7,655,759 | 20.6 | 10,011,224 | 27.0 |
| Warfarin | 78,612,618 | 7,316,279 | 9.3 | 20,484,740 | 26.1 |
| Phenytoin extended | 64,340,706 | 5,899,264 | 9.2 | 11,337,251 | 17.6 |
| Ranitidine | 176,288,934 | 5,876,778 | 3.3 | 9,455,660 | 5.4 |
| Total of selected drugs | 908,924,370 | 109,482,614 | 12.0 | 221,878,540 | 24.4 |